Biosion, In Global For Global, antibody-drug conjugate, bosakitug TSLP, SynTracer+Flexibody+H3

Professional quality

2021-12-13

Biosion, Inc. Licenses BSI04702, An Anti-TROP-2 mAb, to OBI Pharma, Inc. for Worldwide Development and Commercialization Rights as an Antibody Drug Conjugate and Other Derivative Products

2021-12-13

Biosion, Inc. Licenses BSI04702, An Anti-TROP-2 mAb, to OBI Pharma, Inc. for Worldwide Development and Commercialization Rights as an Antibody Drug Conjugate and Other Derivative Products

This license agreement continues to build on Biosion’s efforts to create and develop meaningful biologics to treat resistant, relapsed and residual disease for patients worldwide.

2021-12-09

Biosion, Inc. Completed Pre-B+ Round Financing to Accelerate the Discovery and Global Development of Its Innovative Biologics Pipeline

2021-12-09

Biosion, Inc. Completed Pre-B+ Round Financing to Accelerate the Discovery and Global Development of Its Innovative Biologics Pipeline

New funding will strengthen Biosion’s “In Global For Global” positioning by accelerating its clinical pipeline and expanding its global biologics development teams

2021-11-12

Biosion, Inc. and Celldex present positive preclinical data at SITC 2021. CDX-585 is the first compound from Celldex’s research and collaboration agreement with Biosion, Inc. and combines Celldex’s IL

2021-11-12

Biosion, Inc. and Celldex present positive preclinical data at SITC 2021. CDX-585 is the first compound from Celldex’s research and collaboration agreement with Biosion, Inc. and combines Celldex’s IL

HAMPTON, N.J., November 12, 2021 — Celldex Therapeutics, Inc. today announced positive preclinical data from CDX-585, the Company’s bispecific antibody with dual targeting of ILT4 and PD-1 checkpoint pathways, developed from its bispecific antibody platform. These data were presented in a poster ses

Biosion is a global biotechnology company that is currently in the clinical stage.

In Global For Global

News and Information

Biosion, Inc. Licenses BSI04702, An Anti-TROP-2 mAb, to OBI Pharma, Inc. for Worldwide Development and Commercialization Rights as an Antibody Drug Conjugate and Other Derivative Products

Biosion, Inc. Licenses BSI04702, An Anti-TROP-2 mAb, to OBI Pharma, Inc. for Worldwide Development and Commercialization Rights as an Antibody Drug Conjugate and Other Derivative Products

Biosion, Inc. Completed Pre-B+ Round Financing to Accelerate the Discovery and Global Development of Its Innovative Biologics Pipeline

Biosion, Inc. Completed Pre-B+ Round Financing to Accelerate the Discovery and Global Development of Its Innovative Biologics Pipeline

Biosion, Inc. and Celldex present positive preclinical data at SITC 2021. CDX-585 is the first compound from Celldex’s research and collaboration agreement with Biosion, Inc. and combines Celldex’s IL

Biosion, Inc. and Celldex present positive preclinical data at SITC 2021. CDX-585 is the first compound from Celldex’s research and collaboration agreement with Biosion, Inc. and combines Celldex’s IL

Quick Links